Ian E. Smith, MD, FRCP, FRCPE

Use of continuous-infusion 5-fluorouracil (5-FU) for the treatment of metastatic breast cancer has met with some success in recent years. In order to build on this experience, investigators at the Royal Marsden Hospital and

Letrozole (Femara) is a nonsteroidal aromatase inhibitor that is approximately 10,000 times as potent as aminoglutethimide in vivo. Two pivotal multinational phase III trials have compared letrozole (0.5 and 2.5 mg/d) against megestrol acetate and aminoglutethimide, respectively, in patients with locally advanced or metastatic breast cancer.